SCHEMBL1336997

SCHEMBL1336997

Cn1c(=O)c(-c2ccc(F)cc2)cc2c3ccccc3n(C)c21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 3/20 0.49
▸ ATM Q13315 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.46
▸ KDM4E B2RXH2 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ GPR3 P46089 1/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ PDE10A Q9Y233 1/20 0.40
▸ CDC25A P30304 1/20 0.40
▸ CDC25C P30307 1/20 0.40
▸ HKDC1 Q2TB90 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HSP90AA1 P07900 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337392 0.86 HSD17B10 (0.46) HSD17B10KDM4EALDH1A1HPGDNPSR1
SCHEMBL1339132 0.86 HSD17B10 (0.46) HSD17B10KDM4EALDH1A1HPGDNPSR1
SCHEMBL3867031 0.84 KDM4E (0.51) HSD17B10KDM4EALDH1A1HPGDNPSR1
SCHEMBL1338652 0.82 ATM (0.47) MAPK14ATMHSD17B10KDM4EALDH1A1
SCHEMBL1339208 0.80 KDM4E (0.42) KDM4EALDH1A1HPGDKMT2ASMN1; SMN2
SCHEMBL1338152 0.80 DGKI (0.42) MAPK14KDM4EALDH1A1RXFP1POLB
SCHEMBL1338537 0.79 L3MBTL1 (0.44) MAPK14IDO1
SCHEMBL1339122 0.78 MAPK14 (0.35) MAPK14HSD17B10KDM4EALDH1A1SMN1; SMN2
SCHEMBL4760594 0.78 AHR (0.38) MAPK14ATMKDM4EALDH1A1HPGD
SCHEMBL1339490 0.77 CHRNA7 (0.40) HSD17B10KDM4EALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 MAPK14 3487/4885ATM 2693/4885HSD17B10 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback